Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and tetracycline

gefitinib has been researched along with tetracycline in 10 studies

Compound Research Comparison

Studies
(gefitinib)		Trials
(gefitinib)		Recent Studies (post-2010)
(gefitinib)		Studies
(tetracycline)		Trials
(tetracycline)		Recent Studies (post-2010) (tetracycline)
5,2315662,91921,5249773,656

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)tetracycline (IC50)
90-kda heat shock protein beta HSP90 beta, partialHomo sapiens (human)22.4474
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)22.4474
tyrosine-protein phosphatase non-receptor type 7 isoform 2Homo sapiens (human)8.33
30S ribosomal protein S6Escherichia coli K-124.58
30S ribosomal protein S7Escherichia coli K-124.58
50S ribosomal protein L15Escherichia coli K-124.58
50S ribosomal protein L10Escherichia coli K-124.58
50S ribosomal protein L11Escherichia coli K-124.58
50S ribosomal protein L7/L12Escherichia coli K-124.58
50S ribosomal protein L19Escherichia coli K-124.58
50S ribosomal protein L1Escherichia coli K-124.58
50S ribosomal protein L20Escherichia coli K-124.58
50S ribosomal protein L27Escherichia coli K-124.58
50S ribosomal protein L28Escherichia coli K-124.58
50S ribosomal protein L29Escherichia coli K-124.58
50S ribosomal protein L31Escherichia coli K-124.58
50S ribosomal protein L31 type BEscherichia coli K-124.58
50S ribosomal protein L32Escherichia coli K-124.58
50S ribosomal protein L33Escherichia coli K-124.58
50S ribosomal protein L34Escherichia coli K-124.58
50S ribosomal protein L35Escherichia coli K-124.58
50S ribosomal protein L36Escherichia coli K-124.58
30S ribosomal protein S10Escherichia coli K-124.58
30S ribosomal protein S11Escherichia coli K-124.58
30S ribosomal protein S12Escherichia coli K-124.58
30S ribosomal protein S13Escherichia coli K-124.58
30S ribosomal protein S16Escherichia coli K-124.58
30S ribosomal protein S18Escherichia coli K-124.58
30S ribosomal protein S19Escherichia coli K-124.58
30S ribosomal protein S20Escherichia coli K-124.58
30S ribosomal protein S2Escherichia coli K-124.58
30S ribosomal protein S3Escherichia coli K-124.58
30S ribosomal protein S4Escherichia coli K-124.58
30S ribosomal protein S5Escherichia coli K-124.58
30S ribosomal protein S8Escherichia coli K-124.58
30S ribosomal protein S9Escherichia coli K-124.58
50S ribosomal protein L13Escherichia coli K-124.58
50S ribosomal protein L14Escherichia coli K-124.58
50S ribosomal protein L16Escherichia coli K-124.58
50S ribosomal protein L23Escherichia coli K-124.58
30S ribosomal protein S15Escherichia coli K-124.58
50S ribosomal protein L17Escherichia coli K-124.58
50S ribosomal protein L21Escherichia coli K-124.58
50S ribosomal protein L30Escherichia coli K-124.58
50S ribosomal protein L6Escherichia coli K-124.58
30S ribosomal protein S14Escherichia coli K-124.58
30S ribosomal protein S17Escherichia coli K-124.58
30S ribosomal protein S1Escherichia coli K-124.58
50S ribosomal protein L18Escherichia coli K-124.58
Alpha-synucleinHomo sapiens (human)6.06
50S ribosomal protein L2Escherichia coli K-124.58
50S ribosomal protein L3Escherichia coli K-124.58
50S ribosomal protein L24Escherichia coli K-124.58
50S ribosomal protein L4Escherichia coli K-124.58
50S ribosomal protein L22Escherichia coli K-124.58
50S ribosomal protein L5Escherichia coli K-124.58
30S ribosomal protein S21Escherichia coli K-124.58
50S ribosomal protein L25Escherichia coli K-124.58
50S ribosomal protein L36 2Escherichia coli K-124.58

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (40.00)29.6817
2010's6 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Ekins, S; Williams, AJ; Xu, JJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Fishkin, PA; Gross, HM; Jatoi, A; Johnson, DB; Kahanic, SP; Loprinzi, CL; Novotny, PJ; Rowland, K; Schaefer, PL; Sloan, JA; Tschetter, LK1
Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA1

Reviews

1 review(s) available for gefitinib and tetracycline

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for gefitinib and tetracycline

ArticleYear
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
    Cancer, 2008, Aug-15, Volume: 113, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Evaluation; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Placebos; Quality of Life; Quinazolines; Tetracycline

2008

Other Studies

8 other study(ies) available for gefitinib and tetracycline

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
    Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:8

    Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mometasone Furoate; Neoplasms; Pregnadienediols; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Quinazolines; Radiodermatitis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sunscreening Agents; Surveys and Questionnaires; Terminology as Topic; Tetracycline

2012